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Eumelanin + Phaeomelanin (mixed melanin)











The essential components of the isolated limb perfusion 
circuit are shown diagrammatically.
Figure 4
From the foot of the operating table, with the patient 
supine, the right leg (to be treated) is seen wrapped in a 
heated water blanket. Wires from thermistor probes 
attached to the limb are seen emerging from beneath the 
blanket at the bottom of the illustration.
Figure 5
View of the operative exposure of the right external iliac 
vessels, after retroperitoneal dissection, seen from the 
patient's right. The tips of the cannulae are passed 
distally (left to right) and lie below the level of the 
inguinal ligament. Satisfactory positions have been 
achieved and the cannulae are secured with cotton snares.
Figure 6
View of the lateral part of the right buttock and upper 
thigh during isolated limb perfusion (patient's feet to 
right). The Esmarch tourniquet is anchored by a Steinmann 
pin (top, middle) driven into the anterior superior iliac 
spine. Distal to the tourniquet the skin of the upper 
anterior thigh is stained with fluorescein.
Figure 7
View of the right iliac fossa and upper anterior thigh 
immediately after isolated limb perfusion. The skin wound 
has been closed with interrupted nylon over a fine bore 
suction drain. Note that the skin is stained with 
fluorescein up to the marks of the tourniquet, but there 







































































Response of our first patient (M.B., female) treated with 
isolated limb perfusion.
A Before isolated limb perfusion.
B Two weeks after isolated limb perfusion.
Figure 10A
Patient F.B. with 
satellitosis and in 
transit recurrent
melanoma - note the 
pigmentation of prior 
radiotherapy.
These lesions had 
progressed despite 




Five days after 
isolated limb perfusion 
the lesions are 
necrotic (cf. Fig. IOC)
Figure IOC
Close-up view of necrotic melanoma nodule at five days 
after isolated limb perfusion (lesion below skin graft on 
Fig. 10B).
Figure 10D
The limb of patient 
F.B. one month after 
isolated limb perfusion 
the lesions have 
become flattened and 
crusted over (cf. 10A & 
B)
Figure 11
The right leg of this patient (C.M.) was treated according 
to the M.R.C. protocol (2mg/kg by divided dose). At 14 
days after isolated limb perfusion the limb is painful and 
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The right leg of this patient (T.T.) was treated according 
to the protocol of Group C in our pharmacokinetic studies 
(1.75mg/kg by divided dose). The painful limb is 
oedematous; the skin is erythematous with exfoliation and 
blistering over the dorsum of the foot (Wieberdink grade 
IV reaction).
Figure 23
Untreated control B0008 human melanoma spheroid 
regrowing normally at 11 days (800jum diameter)
Treated B0008 spheroid which is just beginning to 





seed at high density in 
agar base-coated flasks 
clump formation
small spheroids (250microns)
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Classification of patients with dysplastic naevi proposed 
by Kraemer and colleagues36
Type A Sporadic, no family history
Type B Dysplastic naevi in family
Type C Dysplastic naevi plus melanoma, but no 
family history of dysplastic naevi
Type D-l - One family member with melanoma and 
dysplastic naevi





Original three stage clinical staging system for 
cutaneous malignant melanoma
Staae Criteria
I Localised primary malignant melanoma 
or "local recurrence"
II Metastases to regional lymph nodes 
or in transit metastases
III Disseminated malignant melanoma, 
beyond draining lymph nodes
91
Table 3
M.D. Anderson clinical staging system108 for cutaneous 
malignant melanoma*
Stacre Criteria
I Localised primary melanoma
A - Primary intact 
B - Primary locally excised 
C - Multiple primaries
II Local recurrence or primary with
local peripheral nodules <3cm
III Regional metastases
A - in transit 
B - lymph nodes 
AB - in transit plus 
lymph nodes
IV Systemic metastases
The original M.D. Anderson staging system distinguished 
between stage 0, "superficial melanoma" and stage I, "more
i n o
deeply invasive melanoma" . Stage 0 has now been







of invasion in primary cutaneous malignant
Level Criteria
I Confined to the epidermis (in situ)
II Invasion of the papillary dermis
III Filling and distortion of the papillary 
dermis
IV Invasion of the reticular dermis
V Invasion of the sub-cutaneous fat
93
Table 5
Summary of study cruoted as evidence in favour of 
"elective lymph node dissection" (ELND) in the management 
of cutaneous malignant melanoma.
Authors: Milton,Shaw et al,1982221
Type of study: Single centre, retrospective 
Non-randomised
Length of follow-up: 2-32 years, median not given
No. patients: 1319, Clinical Stage I,
Sites: Axial and limb
No. Excision alone: 939
No. ELND: 380
No. ELND with involved nodes: 19 (5%)
Subgroups benefiting from ELND: Males with limb lesions 
of Breslow 1.6-3mm
Morbidity of ELND: "acceptably low"
Mortality associated with ELND: 2 deaths
94
Table 6
Summary of study quoted as evidence in favour of
"elective lymph node dissection" (ELND) in the management
of cutaneous malignant melanoma.
Balch,Soong et al,1982168 
Two centre, Sydney And Alabama 
Part prospective, non-randomised 
2-25 years, median not given 
Alabama, 676 Clinical Stage I






No. ELND with involved nodes: Not given
Subgroups benefiting from ELND: All Breslow 1.5-3.99mm
Males Breslow 0.76-1.5mm 
Morbidity of ELND: No comment
Mortality associated with ELND: No comment
Authors:
Type of study:
Length of follow-up: 
No. patients:
Sites:




Summary of study cruoted as evidence in favour of 
"elective lymph node dissection" (ELND) in the management 
of cutaneous malignant melanoma.
Authors: McCarthy et al,1985238
Type of study: Single centre
Part prospective, non-randomised
Length of follow-up: 10 year
No. patients: 2347 Clinical stage I
Sites: trunk and limb
No. Excision alone: 1719
No. ELND: 628
No. ELND with involved nodes: 27 (4%)
? Benefit from ELND: 1.6-3mm Breslow primaries 
Men > women
Morbidity of ELND: No comment
Mortality associated with ELND: No comment
96
Table 8
Summarv of studv auoted as evidence in favour of 
"elective lymph node dissection" (ELND) in the management 
of cutaneous malignant melanoma.
Authors: Reintgen,Cox et al,1983222
Type of study: Regional referral centre 
(Surgical treatment before referral) 
Retrospective
Length of follow-up: 2-10 years, median not given
No. patients: 613 with "complete staging" 
Breslow 0.76-4mm, Clinical Stage I
Sites: Trunk and limb
No. Excision alone: 426
No. ELND: 187
No. ELND with involved nodes: Not given
? Benefit from ELND: Overall borderline statistical 
significance, significant benefit in 
intermediate thickness group
Morbidity of ELND: No comment
Mortality associated with ELND: No comment
97
Table 9
Summarv of study auoted as evidence in favour of 
"elective lymph node dissection" (ELND) in the management 
of cutaneous malignant melanoma.
Authors: Fortner et al, 1977239
Type of study: Regional referral centre
Retrospective
Length of follow-up: 5-10 years
No. patients: 404 Clinical Stage I
No Breslow data
Sites: Trunk and limb
No. Excision alone: 145
No. ELND: 259
No. ELND with involved nodes: 40 (15%)
? Benefit from ELND : 9 patients had only micro-
metastases and 6/9 ("67%") survived 10 years
Morbidity of ELND: No comment
Mortality associated with ELND: No comment
98
Table 10
Summary of study quoted as evidence in favour of
"elective lymph node dissection" (ELND) in the management
of cutaneous malignant melanoma.
Authors:
Type of study:
Wanebo et al, 1975132 
Retrospective
Length of follow-up: 
No. patients:
Sites:
No. Excision alone: 
No. ELND:
5-9 years




No. ELND with involved nodes: 14 (12.4%)
? Benefit from ELND: ? for Clark level III
Morbidity of ELND:





Summary of study quoted as evidence against routine
"elective lymph node dissection" (ELND) in the management
of cutaneous malignant melanoma.
Authors: Veronesi, Adamus et 31,1977225
Veronesi, Adamus et al,1982226
Type of study: Multi-centre Prospectively Randomised
Length of follow-up: updated to average 10.4 years217
No. patients: 553
Stage I, inc. satellites within 5cm
Site: distal 2/3 of limb
No. Excision alone: 286
No. ELND: 267
No. ELND with involved nodes 19.7-
? benefit from ELND: None
Morbidity of ELND: No comment
Mortality associated with ELND: No comment
100
Table 12
Summary of studv emoted as evidence against routine 
"elective lymph node dissection" (ELND) in the management 
of cutaneous malignant melanoma.
Authors: Sim, Taylor et al, 1978223 
Sim, Taylor et al, 1986221
Type of study: Prospective randomised, 
single centre
Length of follow-up: Updated to 13 years (median 4.5)
No. patients: 171 Clinical Stage I
Site: 34 trunk, 137 limb
No. excision alone: 62
No. ELND: 55 delayed, 
54 immediate
?benefit from ELND: None
Morbidity of ELND: lymphoedema 32/109 
seroma 15/109 
delayed healing 7/109
Mortality associated with ELND: Nil
101
Table 13
Objective response rates after isolated limb perfusion for 




Name(date)No total CR PR CR+PR:
Bulman (1980)338 29 7 7 48
Rosin (1980)211 80 21 29 62
Jonsson (1983)360 15 1 10 73
Lejeune (1983)339 23 15 6 91
Vaglini (1985)341 32 18 8 81
Storm (1985)340 26 21 0 81
Kroon (1987)344 18 7 8 83
^CR = Complete response )
PR = Partial response ) U-I.C.C. Criteria (see 1.5.4)
102
Table 14
Survival after isolated limb perfusion for 





Krementz (1986)318 39 II 68% 5YS
Stehlin (1979)352 27 II-IIIAB 52.5% 5YS
Shingleton (1975)334 43 II-IIIAB 28% 5YS
Rosin (1980)211 130 II-IIIAB 34% 3YS
Stehlin (1979)352 _ •k30 - IIIA 74% 5YS
Krementz (1986)318 70 IIIA 29% 5YS
Storm (1985)340 26 IIIA-IIIAB 25% 3YS
Krementz (1986)318 96 IIIAB 31% 5YS
Hartley# (1987)347 22 II-IIIA 58% 5YS
26 IIIB 70.5% 5YS
17 IIIAB 29% 5YS
Baas (1988)348 36 II 74% 5YS
45 IIIA 67% 5YS
28 IIIAB 40% 5YS
^Subgroup treated by "hyperthermic" limb perfusion




Survival after surgery plus adjuvant isolated limb






















110 >1 .5mm None 78% 5YS
Janoff361
(1982)
122 Stage I None **81% 5YS
Rege364
(1983)























* Clark IV or V
** disease-free 
 ^ YS = years survival,
Control results in (....)
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Table 16
Clinical details of 42 candidates for therapeutic isolated 
limb perfusion
SEX
10 men 32 women
AGE (whole group) 









TIME SINCE TREATMENT OF PRIMARY MELANOMA 
median 18 months, (range 1-156 months)
FURTHER TREATMENT SINCE DEFINITIVE SURGERY FOR PRIMARY
a) Surgery:
No. procedures since primary surgery 
0 1 2 3 4 5  7 18
No. pts. 7 16 8 6 2 1  1 1
b) Chemotherapy: Six patients, (none given melphalan)
c) Radiotherapy: One patient










Clinical details of 15 patients treated by adjuvant 
isolated limb perfusion
SEX
4 men 11 women
AGE
mean 48.8 years (S.D. 12.9), range 24-69
SITE OF PRIMARY 
thigh leg * foot subungual
No. Pts. 2 8 3 2
BRESLOW THICKNESS 
mean 4.3mm (S.D. 1.74), range 2.3-7.5
106
Table 18
Response rates to therapeutic isolated limb perfusion
a) in all 21 cases with measurable tumour treated by 
therapeutic perfusion (including 4 repeat perfusions)
#CR PR NR Total
No. pts•(%) 9(43) 11(52) 1(5) 21(100)
b) in the 17 cases where ILP was performed for the first 
time
#CR PR NR Total
No. pts.(%) 9(52) 8(48) 0 17(100)
#KEY
CR = Complete response ) . . .
PR = Partial response ) U.I.C.C. Criteria (see 1.5.4)
NR = No or minimal Response
Table 19
Pattern of recurrent disease in 38 patients treated by
therapeutic isolated limb perfusion
Site of 
Subsecruent
Recurrence No.Pts. Time in months 
median (range)
None 16 8 (4-33)
Limb only 3 8 (5-8)
Limb+node 1 8
Limb + systemic 5 8 (6-10)
+ 10 (8-24)
Limb + node + systemic 2 2+7+7, 4+4+10
Node + systemic 2 6+10, 7+9
Systemic 9 10 (1-24)
108
Table 20
Recurrence and metastasis after adjuvant 
perfusion in 15 patients (cf. Table 15)
isolated limb
Site of recurrence No.Pts. Time in months
median (range)
None, disease-free 11 29 (6-37)




Physiology of isolated limb perfusion






b) Tissue temperatures before and during isolated limb
perfusioni.
i) Calf muscle versus skin temperatures AUCs
(11 patients)













Wilcoxon signed rank test, value 25, N.S.
ii) Limb surface temperatures (60 perfusions)
mean temperature ° C (Std.dev.)
Pre-ILP Start ILP End ILP
Calf 32.9 (1.6) 36.9 (1.2) 38. 4 (1.4)
Thigh 32.8 (1.8) 36.7 (1.6) 38 (1.2)
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Table 22
Physiology of isolated limb perfusion 
Table 21)
(continued from
c) Gas tensions and acid/base status in the perfusate
i) Mean ARTERIAL values (Std1. dev.) n = 22 perfusions
Time in minutes
15 30 55
Pq 2 mmHg 408 (50) 409 (58) 421 (62)
PCq 2 mmHg 21 (6.2) 18.6 (6.3) 16.4 (5.9)
pH 7.49 (0.06) 7.55 (0.1) 7.61 (0.1)
Base excess -5 (2.1) -3 (1.9) -1.3 (2.1)
ii) Mean VENOUS values (Std. dev.) n = 22 perfusions
Time in minutes
15 30 55
Pq 2 mmHg 49.4 (8.5) 44.9 (7.5) 40.3 (10)
PCq 2 26.5 (5.7) 23.5 (6.2) 19.9 (5.7)
pH 7.42 (0.05) 7.49 (0.1) 7.56 (0.1)
Base excess -4.8 (2) -3.1 (1.9) -1 (2)
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Table 23
Complications and toxicity in 61 isolated limb perfusions
a) General Complications
Problem No. Patients Comments
Deep venous 
thrombosis
2 one week and two 
months after ILP
Bleeding 1 wound re-explored 
immediately post-op
Angina and postural 
hypotension









Problem No. Patients Comments
Severe cellulitis 
and desquamation
2 1 with interdigital 
sepsis
Nerve symptoms 3 1 arm pain 
1 dysaesthesiae 
1 femoral nerve palsy -> 
temporary quadriceps paresis
Muscle symptoms 1 severe pain, swelling, 
calf tenderness and late 
temporarary foot drop





(<3xl09/litre) 6 usually delayed 
1 with late alopecia
Thrombocytopenia 1 <100xl09/litre
Pancytopenia 1 Haemoglobin 8.6g/dl, 
Platelets 23, WBC 1
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Table 24
Scottish Melanoma Group 
registered in 197973.
5-year survival rates for patients
Breslow thickness No . oatients 5vr. survival
0-1.49mm 92 93%
1.5-3.49mm 78 67%
3.5mm and over • 81. 37%
ALL patients 251 62%
113
Table 25
Wieberdink grading system for description of the reaction 
of normal tissues^ to isolated limb perfusion with 
melphalan400
Grade Description of reaction
I No subjective or objective evidence of reaction
II Slight erythema and /or oedema
III Considerable erythema and or oedema with some •
blistering; slightly disturbed motility possible
IV Extensive epidermolysis and/or obvious damage to 
the deep tissues, causing definite functional 
disturbances; threatening or manifest 
compartment syndromes
V Reaction which may necessitate amputation
^Peak reaction determines grading
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Table 26
MELPHALAN PHARMACOKINETICS IN ISOLATED LIMB 
Group A results, 11 patients treated with 
1.5mg/kg body weight, given as a single bolus 
Fig.13, 14 & 18).







of mean S.E.M. mean S.E.M.
Sample (std.dev.) (std.dev.)
(mins.)
2 54.2 (35.6) 11.3 74.5(30.3) 9.6
5 45 (14.9) • 4.5 40 (12.3) 3.7
10 33.3 (8.9) 2.7 29.3 (9.1) 2.7
15 24.2 (10) 3 23.5 (11) 3.3
20 19.4 (7-1) 2.1 16.7 (6.6) 1.98
25 15.3 (5.1) 1.53 13.9 (3.6) 1.09
30 14 (5.1) 1.61 12.6 (4.3) 1.3
35 12.7 (4.8) 1.45 11.9 (4.3) 1.29
40 11.7 (3.7) 1.12 9.1 (2.7) 0.83
45 9.81 (3.3) 0.98 8.7 (2) 0.6
50 8.35 (3.8) 1.14 8.37(4.35) 1.31







15 0.25 (0.37) 0.11
30 0.35 (0.47) 0.14
60 0.27 (0.39) 0.12
75 0.29 (0.33) 0.1
90 0.58 (0.58) 0.17
120 0.76 (0.93) 0.28
150 0.61 (0.67) 0.2
180 0.4 (0.63) 0.19
240 0.31 (0.55) 0.17







PHARMACOKINETICS IN ISOLATED LIMB PERFUSION: 
results, 9 patients treated with melphalan 
body weight, given as a single bolus (see also 
14) .




of mean S.E.M. mean S.E.M.
Sample (std. dev.) (std.dev.)
(mins.)
2 156.2 (128) 42.6 91.6 58.9) 19.6
5 75. 3 (44.4) 14.8 66.1 33.5) 11.2
10 58.9 (40.5) 13 . 5 45.3 20.2) 6.7
15 40.7 (17.7) 5.9 37.1 15.5) 5.2
20 32.3 (14.2) 4.7 32.4 13.1) 4 . 37
25 29.7 (15.5) 5.17 26.1 11.8) 3.93
30 25.4 (13.8) 4.6 24.5 12.9) 4.3
35 22.9 (10.7) 3.57 20.6 8.11) 2.7
40 21.6 (10.7) 3 .57 18.8 9) 3
45 19.8 (8.61) 2.87 17.5 7.5) 2.5
50 17.8 (10.3) 3.43 16.3 8.3) 2.77







15 0. 02 (0.06) 0.02
30 0. 02 (0.05) 0.02
60 0. 03 (0.08) 0. 03
75 0. 05 (0.08) 0. 03
90 0.5 (0.28) 0. 09
120 0.53 (0.37) 0.12
150 0.43 (0.57) 0.19
180 0.39 (0.54) 0.18
240 0.37 (0.64) 0.21
300 0.4 (0.93) 0.31
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Table 28
MELPHALAN PHARMACOKINETICS IN ISOLATED LIMB PERFUSION: 
Group C results, 6 patients treated with melphalan given 
in three aliquots at 0,15, and 30 minutes, to total dose 
of 1.75mg/kg body weight.(see also Fig. 20).




of mean S.E.M. mean S.E.M.
Sample (std.dev.) (std. dev.)
(mins.)
2 41.8 (23.1) 9.4 29.1 (19.5) 7.96
5 25.9 (8.4) 3.43 23.3 (7.3) 2.98
10 20.5 (7.8) 3.18 17.5 (V) 2.86
15 17.9 (6.8) 2.78 * 15 (5) 2 . 04
20 44 (22.8) 9.3 43.4 (24.6) 10.04
25 31 (10.9) 4.45 30 (11.7) 4.78
30 24.7 (8.1) 3 .31 22.1 (7.4) 3
35 44 (16) 6.5 41. 6 (13.9) 5. 68
40 36.3 (11) 4 .49 30.9 (10) 4. 08
45 29.3 (9) 3.67 26.1 (8) 3.27
50 25.8 (7.27) 2.97 23 . 3 (7.2) 2.94





























MELPHALAN PHARMACOKINETICS IN ISOLATED LIMB PERFUSION: 
Dose of melphalan, perfusate AUCa and AUCV data for 
individual patients in Groups A, B and C compared with the 
AUCq.qq of systemic concentrations of melphalan (AUCg) .
The unit for AUC is the /xg. min/ml
Group A (1.5mcr/kcr bolus)
Dose (mg) AUCa AUCV AUCS
100 597 504 26.5
75 780 932 48.9
100 919 848 37.5
125 1140 957 30
150 806 748 246
70 1011 579 287
75 858 869 402
100 1324 1360 92.3
125 1229 1187 98.2
130 1158 1087 9.5
100 1508 1105 29.4
median 100 1011 932 48.9
Group B
(1.75mg/kg bolus)
90 1204 984 361
165 1912 * 1680 231
140 1649 * 2083 26.4
70 1144 900 9.5
135 4011 3056 74.3
140 2720 2030 70.1
105 1758 1570 34.6
90 1019 963 27.2
120 1275 1425 24.9
median 120 1649 1570 34.6
Group C
(1.75mg/kg divided dose)
175 2116 ** 1903 62.8
84 1443 * 1326 56.4
100 1129 1018 8.6
100 988 902 9.7
120 2128 2024 25.2
89 2180 1950 35.7
median 100 1779 1614 30.5
Wieberdink Toxicity: * Grade III
(cf. Table 25) ** Grade IV
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Table 30
a) Summary of the values obtained for the 
decribing concentration time curves for 






A a B /3
Group A
Arterial 48.9 0.1 16.8 0.01
Venous 42.8 0.09 13.7 0.01
Group B
Arterial 86.5 0. 09 21.4 0.003
Venous 66.5 0.19 44.3 0.02
b) Values for half-life of alpha and beta
fitted lines (tia and tiB) for arterial2 *2
perfusate in Groups A and B (Fig.14).












Regional toxicity in patients treated by isolated limb











I 1 0 0
II 10 7 4
III 0 2 1
IV 0 0 1






MELPHALAN PHARMACOKINETICS IN ISOLATED LIMB PERFUSION: 
Calculated uptake of melphalan by tissues of the leg 
according to Formula (2) : MELex = (AUCa-AUCv) x Q (see
III.5.6. for derivation). In the clinical groups, mean 
values for AUC and flow are used.
Group A (n=ll)
MELex = (1030 - 925) x 443 = 46.5mg
£
= 44% of mean dose
Group B (n=9)
MELex = (1855 - 1633) x 316 = 70mg
= 60% of mean dose*
Group C (n=6)
MELex = (1664 - 1520) x 331 = 47.6mg
= 43% of mean dose
Each of these values appears to be an overestimate
(III.7.5), unless one proposes that there is very avid
uptake of melphalan by the tissues of the leg. Hence the 
same calculation is applied to the 39°C mock perfusion 
data:
MELex = (3761 - 3705) x 400 = 22mg
= 22% of dose, which is the
proportion "lost" to the cellular components of perfusate
and to the perfusion circuit.
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Table 33
MELPHALAN PHARMACOKINETICS IN ISOLATED LIMB PERFUSION: 
Calculation of melphalan extraction from the perfusate, 
according to the AUCq_3q and AUC30_60, used in Equation 
(2).
Group A
0-30 minutes MELex = (722 - 648) x 443 = 32.8mg^
30-60 minutes MELex = (308 “ 277) x 443 = 13.7mg^
Group B
0-30 minutes MELex = (1248 - 1097) x 316 = 47.7mg^
30-60 minutes MELex = (607 - 536) x 316 = 22.4mg^
Group C
0-30 minutes MELex = (759 ” 701) x 331 = 19.2mg^
30-60 minutes MELex = (905 ” 819) x 331 = 28.5mg#





of melphalan at 55minutes during
[melphalan] Mg/g
Patient Tumour Fat Skin
a) 4.83 1.02 5.36
b) 2.29 0.885 2.2
c) 3.76 0.48 4.95
d) 0.66 1 1.43
e) 1.68 1.045 -
f) 7.85 2.11 5.4
g) 2 1.19 -
h) 3.04 1.56 -
i) 4.64 0.87 2.82
j) 3.2 1.43 1.9
k) 2.8 0.96 3.19
1) 0.74 3.4 4.5
m) 6.125 - 3.25
n) 6.5 3.5 7.16
o) 0.88 1.3 3 .78
Statistical comparisons by Wilcoxon Signed Rank Test:
Tumour versus fat, p<0.01
Tumour versus skin, not significant
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Table 35
Studies of experimental chemotherapy with single agents or 
combinations, in which multicellular tumour spheroids of 
human origin have been used.
Drucr Cell line Reference 
(First author,vear)
Adriamycin * Various including 
melanoma xenografts Jones,1982518
Bladder carcinoma Erlichman,1984519
# Melanoma and 
squamous lung cancer Kohno,1987520










NY 3170 NHIK 3025 




Vinca alakaloids NHIK 3025 Wibe, 1980524 & 1981523-





Supplemented Eagle's MEM, as used for routine cell culture 
in all experiments.
Ingredient^ Quantity
Eagle's MEM (Hepes 25mM) 450ml




+ streptomycin 10, 000/zg/ml)
5ml
Amphotericin B in water (250/zg/ml) 5ml
$A11 ingredients supplied by Gibco, Paisley, Scotland
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Table 37A
Growth of BO008 melanoma spheroids in Experiment 1
Plate No. 'Treatment': 60 minutes at 37°C in...
1 MEM
2 MEM + melphalan 6jug/ml
3 MEM + solvent/diluent (= 32/zg/ml)
4 MEM + melphalan 12/zg/ml
5 MEM + solvent (=32/zg/ml)
6 MEM + melphalan 16/jg/ml
MEDIAN LOG VOLUME (>95% confidence intervals)
DAY PLATE 1 PLATE 2
0 6.91 (6.76-7.06) 7. 05 6.9-7.2)
3 7.42 (7.26-7.58) 7.16 7.02-7.32)
5 7.74 (7.66-7.89) 7.13 7.06-7.34)
9 8.2 (8.13-8.29) 7.19 7-7.34)
12 8.41 (8.38-8.5) 7.21 7.08-7.5)
16 8.61 (8.59-8.68) 7.33 6.96-7.92)
19 8.73 (8.71-8.76) 7.52 7-8.18)





PLATE 3 PLATE 4
0 7 (6.87-7.12) 7.02 6.96-7.12)
3 7.43 (7.3-7.56) 7.14 7.03-7.25)
5 7.72 (7.62-7.8) 7.04 6.88-7.22)
9 8.16 (8.07-8.21) 7.03 6.94-7.2)
12 8.45 (8.42-8.51) 7.08 6.94-7.18)
16 8.64 (8.59-8.66) 7 6.84-7.13)





PLATE 5 PLATE 6
0 7.04 (6.95-7.13) 7.02 6.75-7.27)
3 7.44 (7.29-7.55) 7.14 6.86-7.27)
5 7.66 (7.56-7.86) 6.94 6.71-7.19)
9 8.16 (8.02-8.28) 6.87 6.65-7.16)
12 8.4 (8.3-8.53) 7.12 6.61-7.17)
16 8. 65 (8.54-8.68) 6.92 6.57-7.21)







Regrowth delay of spheroids in Experiment 1










Proportion of spheroids "cured" in Experiment 1












Growth of B0008 melanoma spheroids in Experiment 2
Plate No. 'Treatment': 60 minutes at 37°C in...
1 MEM without amphotericin-B
2 MEM
3 as 1, with melphalan 4/^ g/ml
4 as 2, with melphalan 4/xg/ml
5 as 1, with melphalan 8/xg/ml
6 as 2, with melphalan 8/xg/ml
MEDIAN LOG VOLUME (>95% confidence intervals)
DAY PLATE 1 PLATE 2
0 7.02 (6.88-7.13) 7.01 (6.91-7.10)
3 7.62 (7.51-7.71) 7.65 (7.55-7.68)
6 8.05 (7.96-8.13) 8.04 (7.98-8.12)
10 8.41 (8.37-8.49) 8.44 (8.39-8.49)
13 8.61 (8.53-8.64) 8.62 (8.53-8.66)
17 8.76 (8.73-8.8) 8.78 (8.74-8.81)
PLATE 3 PLATE 4
0 7.05 (6.92-7.17) 7.04 6.96-7.09)
3 7.42 (7.3-7.46) 7.42 7.32-7.46)
6 7.66 (7.5-7.73) 7.59 7.52-7.71)
10 8. 02 (7.93-8.11) 7.94 7.82-8.05)
13 8.22 (8.06-8.36) 8.15 8.01-8.27)
17 8.53 (8.36-8.62) 8.46 8.35-8.59)
21 8.73 (8.64-8.81) 8.63 8.54-8.72)
24 8.73 8.73-8.88)
PLATE 5 PLATE 6
0 7.09 7.05-7.23) 6.95 6.84-7.03)
3 7.41 7.34-7.52) 7.29 7.17-7.38)
6 7.47 7.43-7.64) 7.4 7.31-7.53)
10 7.57 7.57-7.74) 7.48 7.35-7.59)
13 7.64 7.64-7.94) 7.61 7.42-7.69)
17 8.08 8.08-8.32) 8.01 7.72-8.13)
21 8.28 8.28-8.55) 8.27 8.13-8.37)
24 8.46 8.46-8.74) 8.47 8.37-8.56)




Regrowth delay of B0008 melanoma spheroids in Experiment 2











Proportion of spheroids "cured" in Experiment 2












Growth of B0008 melanoma spheroids in Experiment 3 
Plate No. 'Treatment1: 60 minutes ...
1 at 37°C in MEM
2 at 37°C in FZ-free MEM
3 at 43°C in MEM
4 at 43°C in FZ-free MEM
5 at 43 °C in MEM + solvent (=32/xg/ml)
6 at 43°C in FZ-free MEM + solvent (as 5)
MEDIAN LOG VOLUME (>95% confidence intervals)
DAY PLATE 1 PLATE 2
0 6.8 (6.75-6.87) 6.82 (6.76-6.89)
3 7.26 (7.2-7.38) 7.24 (7.18-7.34)
6 7.76 (7.69-7.85) 7.8 (7.7-7.92)
9 8.15 (8.09-8.24) 8.14 (8.11-8.18)
13 8.47 (8.44-8.53) 8.5 (8.46-8.51)
16 8.65 (8.6-8.72) 8.63 (8.58-8.7)
20 8.87 (8.79-8.88) 8.88 (8.88-8.88)
PLATE 3 PLATE 4
0 6.83 (6.73-6.9) ' 6.85 (6.74-6.88)
3 7.14 (7.06-7.24) 7.18 (7.08-7.28)
6 7.89 (7.62-8.37) 7.84 (7.61-7.94)
9 8.02 (7.96-8.07) 8.1 (8-8.12)
13 8.4 (8.34-8.48) 8.42 (8.37-8.45)
16 8.59 (8.55-8.65) 8.61 (8.54-8.69)
20 8.76 (8.73-8.82) 8.78 (8.75-8.84)
PLATE 5 PLATE 6
0 6.88 (6.78-7) 6.84 (6.76-6.89)
3 7.22 (7.17-7.32) 7.2 (7.14-7.28)
6 7.73 (7.68-7.77) 7.78 (7.67-7.79)
9 8.09 (8.07-8.15) 8.12 (8.04-8.17)
13 8.43 (8.4-8.47) 8.44 (8.39-8.47)
16 8.64 (8.59-8.69) 8.59 (8.57-8.64)
20 8.77 (8.73-8.82) 8.82 (8.76-8.88)
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Table 39B
Regrowth delay of B0008 melanoma spheroids in Experiment 3











Proportion of spheroids "cured" in Experiment 3.












Growth of B0010 melanoma spheroids in Experiment 4. 







MEDIAN LOG VOLUME (>95% confidence intervals)
DAY PLATE 1 PLATE 2
0 6.75 (6.69-6.91) 6. 63 (6.59-6.76)
3 6.85 (6.85-6.91) 6.86 (6.78-6.9)
6 6.91 (6.84-6.99) 6.86 (6.83-6.91)
9 6.99 (6.88-7.04) 6.95 (6.9-6.99)
13 7.14 (7.02-7.23) 7.04 (6.97-7.09)
17 7.18 (7.11-7.22) 7. 04 (7-7.11)
23 7.23 (7.13-7.32) 7.08 (7.05-7.17)
31 7.29 (7.15-7.36) 7.11 (7.08-7.14)
PLATE 3 PLATE 4
0 6.67 (6.59-6.9) 6.67 (6.59-6.84)
3 6.78 (6.71-6.97) 6.81 (6.65-6.84)
6 6.86 (6.78-6.94) 6.86 (6.73-6.94)
9 6.92 (6.83-6.99) 6.85 (6.8-7)
13 6.99 (6.95-7.09) 6.96 (6.87-7.05)
17 7.08 (6.99-7.12) 6.96 (6.9-7.09)
23 7.04 (6.99-7.12) 7 (6.9-7.1)
31 7.08 (7-7.18) 7.02 (6.92-7.14)
PLATE 5 PLATE 6
0 6.78 (6.63-7) 6.64 (6.45-6.83)
3 6.87 (6.73-6.95) 6.79 (6.59-6.86)
6 6.9 (6.75-6.96) 6.76 (6.59-6.81)
9 6.98 (6.86-7.1) 6.89 (6.78-7.02)
13 7.02 (6.95-7.1) 7 (6.86-7.08)
17 7.04 (6.94-7.09) 6.96 (6.86-7.09)
23 7.06 (6.95-7.09) 6.96 (6.86-7.04)









The B0010 melanoma spheroids failed to increase volume by 
ten-fold during the period of observation (see Table 42A 
and Fig. 31), hence regrowth delays cannot be calculated.
Table 40C
Proportion of B0010 soheroids "cured" in Experiment 4.












Growth of MEL57 melanoma spheroids in Experiment 5.'







MEDIAN LOG VOLUME (>95% confidence intervals)
DAY PLATE 1 PLATE 2
0 6.66 (6.61-6.73) 6.66 (6.47-6.76)
3 7.4 (7.32-7.47) 7.35 (7.23-7.49)
6 8 (7.87-8.13) 7.71 (7.61-7.82)
10 8.73 (8.56-8.91) 8.06 (7.87-8.15)
13 8.88 (8.88-8.88) 8.29 (8.13-8.42)
17 8.58 (8.29-8.68)
21 8.74 (8.48-8.88)
PLATE 3 PLATE 4
0 6.6 (6.47-6.73) 6.66 (6.59-6.69)
3 7 .14 (7.04-7.22) 7.12 (6.96-7.16)
6 7.35 (7.26-7.52) 7.38 (7.21-7.41)
10 7.65 (7.52-7.74) 7.6 (7.53-7.67)
13 7.76 (7.66-7.88) 7.83 (7.68-7.93)
17 7.93 (7.81-8.16) 7.93 (7.84-8.11)
21 7.94 (7.88-8.15) 8.01 (7.88-8.11)
25 8.08 (7.96-8.25) 8.14 (8.05-8.26)
28 8.11 (7.99-8.27) 8.16 (8.01-8.29)
31 8.15 (8.04-8.25) 8.12 (7.98-8.24)
PLATE 5 PLATE 6
0 6.57 (6.45-6.61) 6.66 (6.5-6.78)
3 6.91 (6.8-7.08) 6.97 (6.87-7.11)
6 7.05 (6.91-7.17) 7.05 (6.96-7.15)
10 7.24 (7.08-7.46) 7.24 (7.12-7.32)
13 7.5 (7.23-7.62) 7.31 (7.25-7.44)
17 7. 63 (7.48-7.82) 7.57 (7.44-7.63)
21 7.7 (7.41-7.87) 7.6 (7.48-7.65)
25 7.9 (7.73-8.08) 7.83 (7.6-7.9)
28 7.92 (7.82-8.04) 7.77 (7.69-7.94)
31 7.91 (7.73-8.04) 7.85 (7.62-8.02)
35 7.87 (7.59-8.08) 7.72 (7.62-7.92)





of MEL57 melanoma 
5.
spheroids











Proportion of spheroids "cured" in Experiment 5.












Growth of MEL57 melanoma spheroids in Experiment 6.
Plate No. 'Treatment1: 60 minutes in ....
1 at 37°C in MEM
2 at 41°C in MEM
3 at 41° C in melphalan 1/xg/ml
4 at 41° C in melphalan 2/ig/ml
5 at 41° C in melphalan 4/xg/ml
6 at 41° C in melphalan 8/xg/ml
MEDIAN LOG VOLUME (>95% confidence intervals)
DAY PLATE 1 PLATE 2
0 6.61 (6.5-6.69) 6.64 (6.55-6.76)
3 7.41 (7.32-7.51) 7.5 (7.44-7.6)
7 8.42 (8.3-8.47) 8.47 (8.36-8.57)
11 8.8 (8.73-8.83) 8.84 (8.76-8.88)
PLATE 3 PLATE 4
0 6.61 (6.45-6.71) 6.67 (6.52-6.76)
3 7.26 (6.97-7.4) 7.29 (7.12-7.4)
7 7.75 (7.52-7.97) 7.68 (7.55-7.88)
11 8.11 (7.84-8.36) 7.96 (7.82-8.03)
16 8.68 (8.45-8.88) 8.27 (8.14-8.38)




PLATE 5 . PLATE 6
0 6.75 (6.67-6.81) 6.69 (6.67-6.86)
3 7.27 (7.14-7.37) 7.13 (7.01-7.2)
7 7.55 (7.5-7.69) 7.17 (7.01-7.32)
11 7.71 (7.6-7.79) 7.37 (7.26-7.55)
16 7.96 (7.91-8.17) 7.58 (7.47-7.71)
19 8.15 (8.06-8.23) 7.69 (7.61-7.77)
23 8.24 (8.14-8.42) 7.86 (7.69-7.92)
26 8.16 (7.99-8.34) 7.9 (7.67-8.01)



















Proportion of spheroids "cured" in Experiment 6.














Growth of B0008 melanoma spheroids in Experiment 7
Plate No. 'Treatment1: 60 minutes ...
1 at 37°C in MEM
2 at 31°C in MEM
3 at 31° C in MEM with melphalan 2/ig/ml
4 at 31° C in MEM with melphalan 4/xg/ml
5 at 31° C in MEM with melphalan 8/xg/ml
6 at 31 °C in MEM with melphalan 16/xg/ml
MEDIAN LOG VOLUME (>95% confidence intervals)
DAY PLATE 1 PLATE 2
0 7.12 (7-7.24) 6.98 (6.87-7.05)
3 7.38 (7.2-7.55) 7.2 (7.1-7.34)
6 7.85 (7.66-7.95) 7.68 (7.55-7.81)
10 8.18 (8.06-8.31) 8.17 (8.05-8.22)
13 8.4 (8.34-8.51) 8.42 (8.34-8.49)
17 8.63 (8.59-8.73) 8.68 (8.62-8.71)
20 8.76 (8.71-8.88) 8.79 (8.76-8.85)
PLATE 3 PLATE 4
0 7.2 (7.02-7.3) 7.1 (7.08-7.27)
3 7.3 (7.21-7.43) 7.28 (7.25-7.48)
6 7.71 (7.5-7.91) 7.67 (7.61-7.79)
10 8.15 (7.88-8.25) 8.06 (7.94-8.17)
13 8.37 (8.18-8.45) 8.3 (8.22-8.37)
17 8.59 (8.44-8.68) 8.58 (8.51-8.62)
20 8.74 (8.68-8.81) 8.7 (8.64-8.77)
22 8.88 (8.73-8.88) 8.79 (8.76-8.88)
PLATE 5 PLATE 6
0 7.12 (7.02-7.32) 7.12 (7.02-7.28)
3 7.26 (7.1-7.37) 7.12 (7.02-7.35)
6 7.41 (7.21-7.46) 7.24 (7.04-7.36)
10 7.53 (7.14-7.6) 7.12 (6.95-7.37)
13 7.81 (7.2-7.85) 7.14 (7.02-7.37)
17 8.22 (7.59-8.28) 7.22 (7.06-7.52)
20 8.41 (7.98-8.48) 7.46 (6.97-7.79)
22 8.51 (8.19-8.58)




Regrowth delay of B0008 melanoma spheroids in Experiment 7











Proportion of spheroids "cured" in Experiment 7












Growth of BOO08 melanoma spheroids in Experiment 8
Plate No. 'Treatment1: 60 minutes in MEM at..
1 37 ° C
2 31 ° C
3 31 °C with melphalan 2/xg/ml
4 31 °C with melphalan 4/Ltg/ml
5 31°C with melphalan 8^g/ml
6 31 °C with melphalan 16/xg/ml
MEDIAN LOG VOLUME (>95% confidence intervals)
DAY PLATE 1 PLATE 2
0 6.88 (6.83-6.96) 6.86 (6.65-6.99)
4 7.6 (7.52-7.71) 7.58 (7.43-7.69)
7 7.96 (7.9-8.05) 7.93 (7.8-8.04)
11 8.35 (8.24-8.38) 8.26 (8.23-8.4)
14 8.54 (8.49-8.6) 8.57 (8.44-8.62)
17 8.67 (8.63-8.72) 8.67 (8.55-8.76)
20 8.82 (8.75-8.88) 8.8 (8.76-8.88)
PLATE 3 PLATE 4
0 6.92 (6.73-7.02) 6.8 (6.71-7.09)
4 7.54 (7.39-7.62) 7.33 (7.25-7.55)
7 7.84 (7.63-7.95) 7.74 (7.64-7.94)
11 8.22 (8.17-8.28) 8.12 (8.05-8.27)
14 8.49 (8.4-8.54) 8.37 (8.28-8.52)
17 8.61 (8.56-8.65) 8.61 (8.48-8.71)
20 8.72 (8.67-8.8) 8.72 (8.58-8.84)
24 8.88 (8.78-8.88) 8-. 88 (8.74-8.88)
PLATE 5 PLATE 6
0 6.81 (6.65-6.95) 6.84 (6.8-6.87)
4 7.12 (7.04-7.25) 7.06 (7-7.16)
7 7.36 (7.21-7.52) 7.1 (6.97-7.22)
11 7.78 (7.65-7.97) 7.24 (7.02-7.4)
14 8.12 (7.92-8.25) 7.57 (7.29-7.73)
17 8.33 (8.1-8.45) 7.86 (7.62-8.02)
20 8.55 (8.33-8.65) 8.1 (7.84-8.3)
24 8.75 (8.55-8.84) 8.34 (8.23-8.51)
27 8.49 (8.43-8.69)




Regrowth delay of B0008 melanoma spheroids in Experiment 8











Proportion of spheroids "cured" in Experiment 8














Growth of B0008 melanoma spheroids in Experiment 9
Plate No. 'Treatment1: 60 minutes in MEM...
1 at 37°C
2 at 35°C
3 at 35°C with melphalan 4/Ljg/ml
4 at 35°C with melphalan 8/zg/ml
MEDIAN LOG VOLUME (>95% confidence intervals)
PLATE 1 PLATE 2
0 6.91 (6.74-7.00) 6.94 (6.76-7.04)
2 7.27 (7.13-7.37) 7.25 (7.14-7.37)
4 7. 65 (7.48-7.68) 7.63 (7.49-7.69)
7 8.07 (7.92-8.11) 8. 04 (7.95-8.06)
9 8.2 (8.07-8.23) 8.17 (8.1-8.21)
14 8.45 (8.37-8.52) 8.47 (8.41-8.5)
16 8.53 (8.46-8.6) 8.51 (8.49-8.55)
DAY PLATE 3 PLATE 4
0 6.88 (6.71-6.94) 6.77 (6.67-6.97)
2 7.16 (7.01-7.21) 7.11 (6.97-7.26)
4 7.36 (7.21-7.45) 7.14 (7-7.32)
7 7.61 (7.44-7.7) 7.18 (7.06-7.38)
9 7.72 (7.62-7.88) 7.3 (7.22-7.47)
14 8.08 (7.99-8.19) 7.51 (7.44-7.6)




Regrowth delay of B0008 melanoma spheroids in Experiment 9









Proportion of spheroids "cured" in Experiment 9
PLATE No. Proportion 
spheroids "













B0008 melanoma spheroids in Experiment 10 
'Treatment1: 60mins at 37°C in...
MEM
MEM with melphalan 4/ig/ml 
MEM with melphalan 8/ig/ml
MEDIAN LOG VOLUME f>95% confidence intervals)
DAY PLATE 1 PLATE 2
0 6.92 (6.36-7.73) 6.96 (6.81-7.12)
2 7.26 (6.52-7.92) 7.18 (7.02-7.36)
7 7.97 (7.21-8.28) 7.5 (7.38-7.66)
10 8.23 (7.66-8.49) 7.75 (7.61-7.8)
14 8.43 (8.07-8.66) 8.03 (7.94-8.12)
18 8.64 (8.29-8.84) 8.31 (8.19-8.36)



















Regrowth delay of B0008 melanoma 
in Experiment 10
spheroids






Proportion of spheroids "cured" in Experiment 10







Growth of B0008 melanoma spheroids in Experiment 11
Plate No. ’Treatment’: 60 minutes at 37°C in..
1 MEM
2 MEM with melphalan 2jug/ml
3 MEM with melphalan 4/itg/ml
4 MEM with melphalan 8/xg/ml
5 MEM with melphalan 12/xg/ml
6 MEM with melphalan 16/zg/ml
MEDIAN LOG VOLUME (>95% confidence intervals}
DAY PLATE 1 PLATE 2
0 7.02 (6.94-7.1) 7.06 (7-7.16)
4 7.8 (7.69-7.84) 7. 63 (7.6-7.73)
7 8.14 (8.1-8.17) 7.98 (7.88-8.03)
11 8.49 (8.47-8.52) 8.36 (8.28-8.38)
18 8.79 (8.77-8.8) 8.69 (8.67-8.74)
21 8.88 (8.82-8.88)
PLATE 3 PLATE 4
0 7.04 (6.92-7.15) 7.03 (6.96-7.09)
4 7.5 (7.41-7.54) 7.33 (7.27-7.41)
7 7.59 (7.52-7.67) 7.39 (7.29-7.44)
11 7.92 (7.82-8.02) 7.45 (7.41-7.56)
18 8.43 (8.22-8.48) 7.46 (7.37-7.57)
21 8.6 (8.42-8.66) 7.55 (7.47-7.77)
25 8.74 (8.63-8.81) 7.84 (7.75-8.03)
29 8.2 (8.01-8.33)
33 8.41 (8.27-8.64)
PLATE 5 PLATE 6
0 7.06 (6.99-7.2) 7.1 (7.01-7.19)
4 7.36 (7.26-7.44) 7.34 (7.29-7.47)
7 7.42 (7.34-7.47) 7.37 (7.29-7.47)
11 7.5 (7.43-7.62) 7.48 (7.44-7.53)
18 7.53 (7.36-7.6) 7.36 (7.31-7.52)
21 7.46 (7.34-7.57) 7.4 (7.25-7.44)
25 7.51 (7.41-7.71) 7.35 (7.24-7.57)
29 7.75 (7.53-8.02) 7.41 (7.35-7.56)
33 8.1 (7.88-8.33) 7. 64 (7.36-8)
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Table 47B
Regrowth delay of B0008 melanoma 
in Experiment 11
spheroids









Proportion of spheroids "cured" in Experiment 11
PLATE No. Proportion 
spheroids "










Growth of B0008 melanoma spheroids in Experiment 12
Plate No. ’Treatment1: 60 minutes at 37°C in...
1 MEM
2 MEM with melphalan 2/ig/ml
3 MEM with melphalan 4jug/ml
4 MEM with melphalan 8/ig/ml
5 MEM with melphalan 12/xg/ml
6 MEM with melphalan 16/xg/ml
MEDIAN LOG VOLUME (>95% confidence intervals) 
DAY PLATE 1 PLATE 2
0 6.76 (6.71-6.88) 6.91 (6.73-7.1)
4 7.55 (7.47-7.63) 7.54 (7.39-7.61)
7 7.95 (7.86-7.99) 7.85 (7.66-7.94)
11 8.33 (8.23-8.42) 8.21 (8.08-8.29)
14 8.52 (8.39-8.59) 8.4 (8.27-8.44)
18 8.65 (8.58-8.73) 8.59 (8.49-8.69)
21 8.77 (8.71-8.85) 8.74 (8.62-8.81)
PLATE 3 PLATE 4
0 6.88 (6.76-6.96) 6.88 (6.83-6.97)
4 7.32 (7.23-7.44) 7.31 (7.21-7.37)
7 7.46 (7.36-7.58) 7.38 (7.23-7.43)
11 7.82 (7.69-7.94) 7.5 (7.43-7.57)
14 8.09 (7.92-8.2) 7.69 (7.56-7.79)
18 8.29 (8.21-8.43) 8.03 (7.88-8.16)
21 8.42 (8.33-8.6) 8.22 (8.07-8.3)
26 8.64 (8.6-8.73) 8.4 (8.3-8.51)
29 8.81 (8.75-8.88) 8.57 (8.47-8.64)
32 8.72 (8.53-8.77)
PLATE 5 PLATE 6
0 6.86 (6.78-6.95) 6.96 (6.84-7.1)
4 7.21 (7.12-7.26) 7.23 (7.18-7.41)
7 7.26 (7.18-7.32) 7.27 (7.22-7.46)
11 7.28 (7.21-7.39) 7.34 (7.25-7.48)
14 7.34 (7.25-7.47) 7.32 (7.21-7.46)
18 7.42 (7.3-7.55) 7.36 (7.28-7.51)
21 7.59 (7.32-7.78) 7.31 (7.21-7.54)
26 7.96 (7.67-8.17) 7.34 (7.22-7.57)
29 8.09 (7.91-8.21) 7.44 (7.21-7.67)
32 8.25 (8.11-8.34) 7.54 (7.27-7.78)
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Table 48B
Regrowth delay of B0008 melanoma 
in Experiment 12
spheroids












Proportion of spheroids "cured" in Experiment 12.
PLATE No. Proportion 
spheroids "

















B0008 melanoma spheroids in Experiment 13
'Treatment1: 60 minutes in MEM..
at 37°C 
at 39 °C
at 39°C with melphalan 2/zg/ml 
at 39 °C with melphalan 4/ig/ml 
at 39°C with melphalan 8/zg/ml
MEDIAN LOG VOLUME (>95% confidence intervals)
DAY PLATE 1 PLATE 2
0 7.16 (7.08-7.4) 7.2 (7.06-7.56)
2 7.4 (7.16-7.92) 7.39 (7.12-7.89)
6 7.94 (7.69-8.32) 7.92 (7.67-8.29)
11 8.41 (8.3-8.64) 8.39 (8.28-8.6)
14 8.6 (8.48-8.74) 8.56 (8.46-8.74)
16 8.68 (8.57-8.74) 8.64 (8.56-8.79)










PLATE 4 PLATE 5
0 6.93 (6.81-7.06) 7.19 (6.94-7.3)
2 6.9 (6.8-7.08) 7.09 (6.83-7.34)
6 6.83 (6.67-7.17) 7.02 (6.91-7.21)
11 7.3 (6.9-8.06) 7.08 (6.92-7.38)
14 7.58 (6.75-8.21) 7.05 (6.81-7.61)
16 7.9 (6.86-8.45) 6.97 (6.8-7.85)
20 8.09 (6.87-8.5) 7.05 (6.84-8.29)
24 8.36 (6.87-8.5) 6.96 (6.81-8.55)
27 8.5 (6.88-8.88) 6.95 (6.87-8.83)
30 8.62 (6.84-8.88) 7.07 (6.95-8.88)
34 8.88 (6.87-8.88) 7.05 (6.86-8.88)
37 8.88 (6.86-8.88) 7.11 (6.52-8.88)
41 8.88 (6.88-8.88) 7.13 (6.94-8.88)
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Table 49B
Regrowth delay of B0008 melanoma 
in Experiment 13
spheroids






Table 4 9 C
Proportion of spheroids "cured" in Experiment 13.
PLATE No. Proportion 
spheroids "









Growth of B0008 melanoma spheroids in Experiment 14
Plate No. 'Treatment': 60 minutes in MEM...
1 at 37 °C
2 at 39°C
3 at 39 °C with melphalan 2/zg/ml
4 at 39 °C with melphalan 4/zg/ml
5 at 39 °C with melphalan 8/xg/ml
6 at 39 °C with melphalan 16jug/ml
MEDIAN LOG VOLUME (>95% confidence intervals)
DAY PLATE 1 PLATE 2
0 7.01 (6.95-7.04) 6. 88 (6.83-7.01)
4 7.88 (7.8-7.91) ,7.79 (7.73-7.89)
7 8.2 (8.14-8.26) 8.17 (8.13-8.2)
11 8.45 (8.41-8.51) 8.43 (8.42-8.44)
14 8.58 (8.51-8.61) 8.56 (8.53-8.58)
18 8.72 (8.65-8.76) 8.72 (8.68-8.73)
21 8.79 (8.67-8.88) 8.75 (8.74-8.77)
DAY PLATE 3 PLATE 4
0 6.9 (6.86-7.04) 6.94 (6.76-6.99)
4 7.64 (7.6-7.69) 7.42 (7.31-7.5)
7 7.97 (7.92-8.04) 7.81 (7.67-8.09)
11 8.28 (8.26-8.32) 8. 08 (8.01-8.13)
14 8.47 (8.43-8.53) 8.3 (8.23-8.34)
18 8.68 (8.64-8.7) 8.52 (8.5-8.58)
21 8.72 (8.69-8.75) 8.63 (8.58-8.71)
26 8.77 (8.72-8.84) 8.8 (8.79-8.88)
DAY PLATE 5 PLATE 6
0 6.91 (6.84-6.97) 6.96 (6.84-7.06)
4 7.21 (7.17-7.28) 7.25 (7.12-7.4)
7 7.28 (7.19-7.36) 7.28 (7.12-7.46)
11 7.31 (7.22-7.39) 7.34 (7.17-7.47)
14 7.4 (7.29-7.55) 7.41 (7.29-7.5)
18 7.92 (7.72-8.09) 7.37 (7.21-7.51)
21 8.09 (7.92-8.23) 7.4 (7.23-7.48)
26 8.42 (8.34-8.54) 7.44 (7.26-7.63)
29 8.63 (8.46-8.7) 7.45 (7.32-7.9)




Regrowth delay of B0008 melanoma 
in Experiment 14
spheroids









Proportion of spheroids "cured" in Experiment 14
PLATE No. Proportion 
spheroids "










Growth of B0008 melanoma spheroids in Experiment 15 
Plate No. 'Treatment': 60 minutes at
at 37°C in MEM 
at 41° C in MEM 
at 41 °C in 2/ig/ml melphalan 
at 41 °C in 4/zg/ml melphalan 
at 41 °C in 8/xg/ml melphalan
MEDIAN LOG VOLUME (>95% confidence intervals)
DAY PLATE 1 PLATE 2
0 6.9 (6.76-7.14) 6.94 (6.77-7.2)
4 7.52 (7.44-7.7) 7.56 (7.47-7.74)
7 7.83 (7.8-7.94) 7.86 (7.79-7.99)
11 8.15 (8.12-8.24) 8.18 (8.1-8.23)
14 8.32 (8.29-8.41) 8. 35 (8.32-8.43)
18 8.56 (8.54-8.62) 8.56 (8.55-8.64)










PLATE 4 PLATE 5
0 7.03 (6.81-7.15) 7. 04 (6.96-7.12)
4 7.27 (7.03-7.39) 7.24 (7.16-7.33)
7 7.34 (7.14-7.49) 7.22 (7.16-7.36)
11 7.4 (7.11-7.63) 7.29 (7.2-7.37)
14 7.54 (7.07-7.81) 7.28 (7.22-7.37)
18 7.86 (7.31-8.12) 7.25 (7.13-7.41)
21 8.08 (7.6-8.35) 7.42 (7.35-7.59)
25 8.34 (7.96-8.52) 7.66 (7.32-7.86)
28 8.49 (8.39-8.59) 7.85 (7.43-8.15)
32 8.59 (8.45-8.7) 8.14 (7.76-8.42)
34 8.29 (7.76-8.42)
39 8.44 (8.1-8.7)
42 8. 63 (8.29-8.7)
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Table 51B
Regrowth delay of B0008 melanoma 
in Experiment 15
spheroids








Proportion of spheroids "cured" in Experiment 15.









Growth of B0008 melanoma spheroids in Experiment 16 
Plate No. 'Treatment1: 60 minutes at ....
1 37°C in MEM
2 42.5°C in MEM
3 42.5°C in melphalan 2/xg/ml
MEDIAN LOG VOLUME (>95% confidence intervals}
DAY PLATE 1 PLATE 2
0 7.08 (6.92-7.2) 7.09 (6.94-7.21)
4 7.42 (7.34-7.52) 7.41 (7.32-7.5)
9 8.04 (7.92-8.12) 8 (7.94-8.08)
11 8.16 (8.14-8.21) 8.14 (8.1-8.19)
14 8.37 (8.31-8.43) 8.36 (8.31-8.44)
18 8.63 (8.55-8.7) 8.62 (8.54-8.69)















Regrowth delay of B0008 melanoma spheroids 
in Experiment 16






Proportion of spheroids "cured" in Experiment 16.











Growth of B0008 melanoma spheroids in Experiment 17
Plate No. 'Treatment1.....
1 60 minutes at 37°C in MEM
2 60 minutes at 42.5°C in MEM
3 60 minutes at 42.5°C in melphalan l/xg/ml
4 60 minutes at 42.5°C in melphalan 2/xg/ml
5 60 minutes at 42.5°C in melphalan 4/xg/ml
6 20 minutes at 42.5°C in melphalan 4/zg/ml
MEDIAN LOG VOLUME (>95% confidence intervals)
DAY PLATE 1 PLATE 2
0 7.06 (6.88-7.14) 7.08 (6.9-7.21)
2 7.39 (7.3-7.5) 7.2 (7.12-7.34)
7 8.08 (8.01-8.17) 7.98 (7.95-8.06)
9 8.23 (8.14-8.31) 8.16 (8.11-8.24)
13 8.51 (8.48-8.58) 8.49 (8.44-8.57)
20 8.78 (8.73-8.82) 8.76 (8.71-8.88)
PLATE 3 PLATE 4
0 7.14 (7.04-7.18) 7.07 (6.96-7.14)
2 7.21 (7*12-7.32) 7.05 (6.99-7.21)
7 7.71 (7.57-7.83) 7.36 (7.22-7.45)
9 7.89 (7.77-8.03) 7.37 (7.24-7.46)
13 8.22 (8.16-8.32) 7.54 (7.44-7.78)
20 8.57 (8.4-8.74) 7.78 (7.52-7.96)
23 8.72 (8.61-8.88) 8.22 (7.79-8.5)
27 8.47 (8.09-8.64)
31 8.73 (8.47-8.86)
PLATE 5 PLATE 6
0 7.14 (7.03-7.22) 7.17 (7.05-7.25)
2 7.14 (7.01-7.21) 7.28 (7.2-7.34)
7 7.28 (7.16-7.4) 7.69 (7.55-7.8)
9 7.21 (7.1-7.39) 7.78 (7.7-7.89)
13 7.35 (7.18-7.59) 8.11 (8-8.2)
20 7.43 (7.06-7.64) 8.42 (8.33-8.55)
23 7.29 (7.09-7.63) 8 . 62 (8.49-8.79)




Regrowth delay of 
in Experiment 17
B0008 melanoma spheroids









6(20min. exposure) 14.89 (11.98-18.01)
Table 53C
Proportion of spheroids "cured" in Experiment 17











6(2 0min. exposure) 1/24 4
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Table 54A
Growth of B0008 melanoma spheroids in Experiment 18
: NO. ’Treatment1: 60 minutes ....
1 at 37°C in MEM
2 * at 42.5°C in MEM (IMMEDIATE PICK-OFF)
3 at 42.5°C in melphalan 0.5 /jlg/ml
4 at 42.5°C in melphalan 1 /xg/ml
5 at 42.5°C in melphalan 2 /zg/ml
6 at 42.5°C in melphalan 4 /ng/ml









































































Regrowth delay of B0008 melanoma 
in Experiment 18
spheroids










Proportion of spheroids "cured11 in Experiment 18





















spheroids in Experiment 19
'Treatment': 60 minutes ....
at 37°C.in MEM 
at 44.5°C in MEM 
at 44.5°C in melphalan 1 fig/ml 
at 44 .5 ° C in melphalan 2 jig/ml 
at 44.5°C in melphalan 4 [iq/ml
spheroids "cured" in Experiment 19











Growth of B0008 melanoma spheroids in Experiment 20
Plate No. 'Treatment1 ....
1 60 minutes at 37°C in MEM
2 15 minutes at 37 °C in melphalan 8/xg/ml
3 30 minutes at 37 °C in melphalan 8/zg/ml
4 15 minutes at 37 °C in melphalan 16/Ltg/ml
5 3 0 minutes at 37 °C in melphalan 16jug/ml
6 60 minutes at 37 °C in melphalan 16jug/ml
MEDIAN LOG VOLUME (>95% confidence intervals)
DAY PLATE 1 PLATE 2
0 6.95 (6.86-7.03) 6.96 (6.88-7.05)
2 7.34 (7.28-7.4) 7.31 (7.21-7.39)
6 8.04 (8.03-8.11) 7.8 (7.71-7.88)
9 8.33 (8.28-8.35) 8.06 (8.04-8.13)
13 8.6 (8.56-8.65) 8.39 (8.36-8.43)







0 6.88 (6.8-6.92) 6.94 (6.88-7.02)
2 7.14 (7.11-7.26) 7.23 (7.15-7.31)
6 7.39 (7.31-7.52) 7.43 (7.37-7.57)
9 7.55 (7.44-7.7) 7.55 (7.44-7.67)
13 7.9 (7.8-8.1) 7.87 (7.71-7.96)
16 8 .17 (7.95-8.29) 8.08 (7.98-8.16)
21 8.56 (8.47-8.62) 8.46 (8.4-8.54)
23 8.65 (8.56-8.71) 8.55 (8.5-8.64)
27 8.8 (8.71-8.85) 8.77 (8.72-8.83)
PLATE 5 PLATE 6
0 6.91 (6.86-7.03) 6.94 (6.91-7.02)
2 7.22 (7.14-7.33) 7.21 (7.11-7.29)
6 7.34 (7.25-7.44) 7.29 (7.23-7.34)
9 7.32 (7.27-7.49) 7.3 (7.18-7.34)
13 7.46 (7.33-7.57) 7.39 (7.24-7.43)
16 7.48 (7.32-7.64) 7.25 (7.21-7.28)
21 7.86 (7.66-8.23) 7.33 (7.25-7.4)
23 8.03 (7.88-8.36) 7.32 (7.2-7.36)
27 8.37 (8.15-8.55) 7.36 (7.29-7.55)
34 8.64 (8.54-8.81) 7.47 (7.27-7.7)
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Table 56B
Regrowth delay of BOO08 melanoma 
in Experiment 20
spheroids









Proportion of spheroids "cured” in Experiment 20












Growth of B0008 melanoma spheroids in Experiment 21
Plate No. 'Treatment' ....
1 60 minutes at 37°C in MEM
2 15 minutes at 37 °C in melphalan 8/zg/ml
3 3 0 minutes at 37°C in melphalan 8/xg/ml
4 60 minutes at 37 °C in melphalan 8jug/ml
5 90 minutes at 37 °C in melphalan 8jLig/ml
6 120 minutes at 37 °C in melphalan 8jzg/ml
MEDIAN LOG VOLUME (>95% confidence intervals)
DAY PLATE 1 PLATE 2
0 6.92 (6.8-7.22) 6.99 6.92-7.06)
3 7.41 (7.33-7.6) 7.31 7.19-7.46)
7 7.94 (7.81-8.03) 7.58 7.44-7.66)
10 8.21 (8.18-8.29)' 7.58 7.38-7.68)
14 8.42 (8.37-8.57) 8.26 8.13-8.35)
17 8.55 (8.5-8.62) 8.31 8.24-8.36)
21 8.77 (8.63-8.85) 8.51 8.42-8.56)
24 8.65 8.54-8.71)
29 8.76 8.63-8.79)
PLATE 3 PLATE 4
0 6.99 (6.86-7.11) 6.95 6.86-7.04)
3 7.22 (7.15-7.31) 7.1 7.01-7.25)
7 7.35 (7.23-7.45) 7.15 7.04-7.3)
10 7.48 (7.35-7.58) 7.13 7.01-7.33)
14 7.82 (7.75-7.88) 7.24 6.96-7.48)
17 8.07 (8.01-8.13) 7.43 6.95-7.67)
21 8.31 (8.22-8.38) 7.73 7.38-8.03)
24 8.48 (8.43-8.52) 7.94 7.7-8.2)
29 8.65 (8.56-8.76) 8.29 7.9-8.49)
32 8.79 (8.72-8.88) 8.47 8.23-8.57)
35 8.64 8.39-8.75)
PLATE 5 PLATE 6
0 6.82 (6.71-6.92) 6.86 6.75-6.94)
3 6.96 (6.9-7.02) 6.97 6.87-7.06)
7 6.98 (6.95-7.12) 6.94 6.86-7.03)
10 6.86 (6.67-6.97) 6.78 6.69-6.88)
14 6.88 (6.83-7.02) 6.69 6.61-6.9)
17 6.92 (6.81-7.01) 6.76 6.65-6.84)
21 6.96 (6.76-7.21) 6.76 6.61-6.95)
24 7 (6.81-7.26) 6.78 6.57-7)
29 7.31 (6.96-7.82) 6.98 6.81-7.12)
32 7.6 (6.95-8.05) 6.76 6.61-7.34)
35 7.98 (7.27-8.41) 6.87 6.65-7.62)
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Regrowth delay of B0008 melanoma spheroids 
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Proportion of spheroids "cured" in Experiment 21










Growth of B0008 melanoma spheroids in Experiment 22
Plate No. 'Treatment1: 30 minutes at ....
1 37°C in MEM
2 31°C in MEM
3 31°C in melphalan 2/zg/ml
4 31°C in melphalan 4;ug/ml
5 31 °C in melphalan 8/ig/ml
6 31 °C in melphalan 16/xg/ml
MEDIAN LOG VOLUME (>95% confidence intervals)
DAY PLATE 1 PLATE 2
0 7.03 (6.87-7.14) 7.02 (6.88-7.18)
4 7.93 (7.81-8.01) 7.94 (7.79-8.01)
7 8.3 (8.25-8.33) 8.29 (8.2-8.38)
10 8.53 (8.49-8.56) 8.51 (8.48-8.6)
13 8.71 (8.65-8.76) 8.66 (8.62-8.76)
17 8.86 (8.83-8.88) 8.83 (8.78-8.88)
PLATE 3 PLATE 4
0 7.13 (7.04-7.23) 7. 05 (6.97-7.15)
4 7.92 (7.82-7.97) 7.8 (7.71-7.89)
7 8.26 (8.21-8.3) 8.14 (8.09-8.21)
10 8.49 (8.45-8.54) 8.38 (8.31-8.4)
13 8.67 (8.61-8.71) 8.57 (8.46-8.6)
17 8.82 (8.76-8.86) 8.75 (8.63-8.83)
PLATE 5 PLATE 6
0 7.11 (7.01-7.2) 7.15 (6.96-7.47)
4 7.74 (7.5-7.85) 7.58 (7.41-7.89)
7 7.98 (7.82-8.07) 7.66 (7.38-8.01)
10 8.19 (8.04-8.31) 7.8 (7.52-8.16)
13 8.43 (8.24-8.49) 8.04 (7.83-8.35)
17 8.66 (8.47-8.69) 8.32 (8.26-8.61)
20 8.81 (8.67-8.86) 8.59 (8.4-8.71)
24 8.74 (8.48-8.88)
27 8.83 (8.56-8.88)
31 8.88 (8 .88-8 .88)
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Regrowth delay of B0008 melanoma 
in Experiment 22
spheroids











Proportion of spheroids "cured" in Experiment 22.
PLATE No. Proportion 
spheroids "










Growth of B0008 melanoma spheroids in Experiment 23.




4 verapamil 5/zg/ml + melphalan 2jug/ml
5 verapamil 10/jg/ml + melphalan 2/zg/ml
6 verapamil 10/xg/ml + melphalan 4/xg/ml
MEDIAN LOG VOLUME (>95% confidence intervals)
DAY PLATE 1 PLATE 2
0 6.92 (6.87-7.05) 6.88 (6.78-6.97)
3 7.52 (7.5-7.6) 7.53 (7.48-7.59)
6 8.09 (8.05-8.13) 8.1 (8.06-8.13)
9 8.42 (8.38-8.67) 8.4 (8.39-8.43)
13 8.67 (8.64-8.69) 8.7 (8.67-8.73)
16 8.79 (8.76-8.81) 8.8 (8.78-8.82)
PLATE 3 PLATE 4
0 6.91 (6.84-7.05) 7.29 (7.03-7.41)
3 7.28 (7.17-7.34) 7.41 (7.31-7.5)
6 7.47 (7.31-7.59) 8.03 (7.9-8.14)
9 7.53 (7.3-7.65) 8.14 (8.05-8.2)
13 7.88 (7.4-7.97) 8.44 (8.41-8.49)
16 8.19 (7.7-8.26) 8.6 (8.55-8.65)
20 8.5 (8.19-8.57) 8.77 (8.74-8.87)
23 8.65 (8.38-8.7)
27 8.81 (8.58-8.88)
PLATE 5 PLATE 6
0 6.96 (6.9-7.09) 6.93 (6.73-7.08)
3 7.4 (7.29-7.51) 7.29 (7.21-7.43)
6 7.89 (7.72-7.92) 7.46 (7.39-7.64)
9 8.16 (8.02-8.23) 7.63 (7.48-7.83)
13 8.48 (8.39-8.52) 8.01 (7.91-8.19)
16 8.64 (8.57-8.68) 8.29 (8.17-8.42)










PLATE No. Median Regrowth >95% confidence
Delay intervals
1 5.29 (4.91-5. 61)
2 4.94 (4.58-5. 25)
3 14.74 (12.55-16.92)
4 11.12 (8 .11-12 . 18)
5 7.5 (6 .66—8 .25)
6 11.78 (10.5-13 .05)
Table 59C
Proportion of spheroids "cured" in Experiment 23.












Growth of B0008 melanoma spheroids in Experiment 24.









verapamil 5jug/ml + 





MEDIAN LOG VOLUME (>95% confidence intervals)
DAY PLATE 1 PLATE 2
0 7.02 (6.91-7.12) 6.97 (6.8-7.1)
2 7.34 (7.27-7.44) 7.31 (7.19-7.4)
5 7.8 (7.73-7.87) 7.78 (7.7-7.88)
9 8.21 (8.17-8.3) 8.23 (8.15-8.28)
12 8.45 (8.42-8.49) 8.45 (8.41-8.49)
16 8.69 (8.62-8.73) 8 . 61 (8.51-8.64)
19 8.79 (8.76-8.85) 8.7 (8.67-8.77)
23 8.88 (8 .88-8 .88)
PLATE 3 PLATE 4
0 7.09 (6.92-7.12) 7.01 (6.91-7.16)
2 7.29 (7.2-7.33) 7.3 (7.17-7.37)
5 7.43 (7.3-7.53) 7.6 (7.46-7.7)
9 7.71 (7.51-7.83) 8.13 (7.91-8.28)
12 8.06 (7.76-8.13) 8.26 (8.17-8.34)
16 8.32 (8.22-8.42) 8.53 (8.43-8.61)
19 8.49 (8.35-8.58) 8.64 (8.57-8.72)
23 8.71 (8.63-8.84) 8.79 (8.73-8.85)
27 8.88 (8.78-8.88)
PLATE 5 PLATE 6
0 6.87 (6.83-7.01) 7.04 (6.92-7.17)
2 7.15 (7.1-7.26) 7.22 (7.11-7.34)
5 7.52 (7.45-7.57) 7.41 (7.31-7.51)
9 7.96 (7.85-8.03) 7.68 (7.55-7.77)
12 8.14 (8.03-8.19) 7.99 (7.82-8.04)
16 8.19 (8.01-8.35) 8.32 (8.18-8.38)
19 8.41 (8.21-8.51) 8.51 (8.31-8.6)




Regrowth delay of B0008 melanoma 
in Experiment 24
spheroids









Proportion of spheroids "cured" in Experiment 24.












Growth of large B0008 melanoma spheroids in Experiment 25. 
Plate No. 'Treatment1: 60 minutes at 37°C in..
1 MEM at pH7
2 MEM at pH7.4
3 MEM at pH8
4 melphalan 4/xg/ml at pH7
5 melphalan 4/zg/ml at pH7.4
6 melphalan 4/ng/ml at pH8
MEDIAN LOG VOLUME (>95% confidence intervals)
DAY PLATE 1 PLATE 2
0 6.97 (6.91-7.06) 7 (6.9-7.15)
4 7.68 (7.63-7.74) 7.74 (7.61-7.78)
8 8.22 (8.19-8.24) 8.19 (8.17-8.24) '
11 8.39 (8.35-8.4) 8.39 (8.35-8.41)
14 8.51 (8.49-8.53) 8.51 (8.49-8.56)
18 8.58 (8.57-8.6) 8.64 (8.58-8.65)
22 8.73 (8.67-8.75) 8.73 (8.71-8.77)
PLATE 3 PLATE 4
0 6.91 (6.86-7.09) 6.97 (6.87-7.05)
4 7.71 (7.65-7.78) 7.51 (7.4-7.6)
8 8.2 (8.18-8.25) 7.74 (7.67-7.79)
11 8.38 (8.36-8.43) 7.94 (7.87-8.02)
14 8.53 (8.48-8.56) 8.17 (8.11-8.22)
18 8.61 (8.57-8.63) 8.35 (8.31-8.42)
22 8.72 (8.7-8.75) 8.58 (8.48-8.65)
25 8.76 (8.69-8.81)
PLATE 5 PLATE 6
0 7.11 (6.97-7.22) 6.96 (6.88-7.02)
4 7.61 (7.59-7.71) 7.52 (7.46-7.63)
8 7.93 (7.86-7.97) 7.94 (7.86-8.04)
11 8.15 (8.07-8.19) 8.17 (8.08-8.24)
14 8.34 (8.28-8.4) 8.34 (8.23-8.41)
18 8.58 (8.46-8.7) 8.5 (8.46-8.63)




Regrowth delay of BO008 melanoma 
in Experiment 25
spheroids









Proportion of spheroids "cured" in Experiment 25.














Growth of small B0008 melanoma spheroids in Experiment 26.
Plate No. 'Treatment1: 60 minutes at 37°C in..
1 MEM at pH7
2 MEM at pH7.4
3 MEM at pH8
4 melphalan 4/xg/ml at pH7
5 melphalan 4/xg/ml at pH7.4
6 melphalan 4/xg/ml at pH8
MEDIAN LOG VOLUME (>95% confidence intervals)
DAY PLATE 1 PLATE 2
0 6.52 6.39-6.73) 6.77 6.59-6.86)
2 6.81 6.71-6.97) 7.04 6.95-7.21)
4 7.11 6.83-7.16) 7.29 7.16-7.45)
7 7.61 7.34-7.99) 7.63 7.55-7.77)
11 7.94 7.77-8.07) 8.08 7.96-8.19)
14 8.15 7.94-8.24) 8.32 8.26-8.41)
17 8.36 8.26-8.42) 8.51 8.4-8.63)
21 8.51 8.4-8.55) 8.63 8.52-8.68)
25 8.71 8.61-8.77) 8.74 8.69-8.83)
PLATE 3 PLATE 4
0 6.76 6.52-6.84) 6.63 6.55-6.75)
2 6.91 6.83-7.05) 6.88 6.73-6.95)
4 7.26 7-7.32) 6.9 6.8-7.01)
7 7.66 7.32-7.73) 6.93 6.65-7.05)
11 8.05 7.89-8.18) 7.07 6.67-7.28)
14 8.24 8.06-8.35) 7.03 6.76-7.62)
17 8.37 8.25-8.45) 7.27 6.96-7.9)
21 8.57 8.44-8.63) 7.86 7.32-8.18)
25 8.71 8.66-8.72) 8.02 7.7-8.44)




PLATE 5 PLATE 6
0 6.49 6.36-6.8) 6.29 6.18-6.39)
2 6.8 6.69-6.91) 6.55 6.45-6.67)
4 6.91 6.76-7.04) 6.76 6.52-6.87)
7 7.03 6.75-7.19) 6.84 6.63-7.1)
11 7.23 7.03-7.43) 7.44 6.87-7.52)
14 7.36 7.09-7.71) 7.81 7.01-7.91)
17 7.62 7.46-7.98) 8 . 06 7.33-8.17)
21 8.03 7.82-8.36) 8.32 7.58-8.46)
25 8.2 8.04-8.54) 8.46 7.93-8.57)
28 8.56 8.32-8.66) 8.72 8.39-8.76)













3 8 .16 (7.62-8.75)
4 19 .84 (17-24.24)
5 16 .27 (11.54-20.72)
6 12 .48 (9.54-16.02)
Table 6 2 C
Proportion of spheroids "cured" in Experiment 26.
PLATE No. Proportion 
spheroids "
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